Depo-Provera: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Medroxyprogesterone acetate

Indications/Uses

Contraception (ovulation suppression), endometriosis, menopausal vasomotor symptoms; hormonally-dependent, recurrent breast cancer in postmenopausal women. Adjunctive &/or palliative treatment of recurrent &/or metastatic endometrial or renal carcinoma.

Dosage/Direction for Use

IM Contraception 150 mg every 12-13 wk (3 mth). Give 1st inj during the 1st 5 days after onset of normal menstrual period. Given at or after 6-wk post-partum period if exclusively breastfeeding. Endometriosis 50 mg wkly or 100 mg every 2 wk for at least 6 mth. Menopausal vasomotor symptoms 150 mg every 12 wk. Endometrial & renal carcinoma Initially 400-1,000 mg wkly then maintain at 400 mg mthly. Breast cancer 500 mg daily for 28 days then maintain at 500 mg twice wkly.

Contraindications

Hypersensitivity. Undiagnosed vag bleeding. Severe liver dysfunction. Known or suspected malignancy of the breast & pregnancy.

MIMS Class

Cancer Hormone Therapy / Depot Contraceptives / Oestrogens, Progesterones & Related Synthetic Drugs

ATC Classification

G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives.

Regulatory Classification

POM

Presentation/Packing

Form

Depo-Provera susp for inj 50 mg/mL

Packing/Price

1's

Depo-Provera

medroxyprogesterone

Manufacturer:

Pfizer Manufacturing